August 17, 2016

VALUATION WATCH: Overvalued stocks now make up 48.21% of our stocks assigned a valuation and 15.36% of those equities are calculated to be overvalued by 20% or more. Eight sectors are calculated to be overvalued.

If you cannot display this bulletin properly, GO HERE

Prime Time

ValuEngine Top STRONG BUY Is FivePrime Therapeutics

We use trading data to provide forecast estimates for a variety of time horizons for almost ever equity in our database. Our Buy/Sell/Hold recommendations are based upon the 1-year forecast return figure. Using valuation and forecast figures, you can rank and rate our covered stocks against each other, to find out, in an objective and systematic way, the most attractive investment targets based on your own risk/reward parameters. We re-calculate the entire database every trading day, so you are assured that every proprietary valuation and forecast datapoint is as up-to-date as possible.

For today's bulletin we used our website's advanced-screening functions to search for the top-rated STRONG BUY US stock with valuation data that meets minimum liquidity requirements. Today, that company is FivePrime Therapeutics (FPRX).

Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California.

ValuEngine continues its STRONG BUY recommendation on Five Prime Therapeutics for 2016-08-16. Based on the information we have gathered and our resulting research, we feel that Five Prime Therapeutics has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE P/E Ratio and Momentum.

You can download a free copy of detailed report on Five Prime Therapeutics from the link below.

ValuEngine Forecast
	Target Price*	Expected Return
1-Month	46.96	1.60%
3-Month	48.14	4.16%
6-Month	49.05	6.12%
1-Year	55.16	19.35%
2-Year	50.49	9.25%
3-Year	47.56	2.90%

Valuation & Rankings
Valuation	0.29% undervalued	Valuation Rank(?)	49
1-M Forecast Return	1.60%	1-M Forecast Return Rank	100
12-M Return	140.10%	Momentum Rank(?)	97
Sharpe Ratio	0.59	Sharpe Ratio Rank(?)	85
5-Y Avg Annual Return	47.76%	5-Y Avg Annual Rtn Rank	99
Volatility	81.43%	Volatility Rank(?)	19
Expected EPS Growth	-124.36%	EPS Growth Rank(?)	2
Market Cap (billions)	1.15	Size Rank	67
Trailing P/E Ratio	5.22	Trailing P/E Rank(?)	98
Forward P/E Ratio	n/a	Forward P/E Ratio Rank	n/a
PEG Ratio	n/a	PEG Ratio Rank	n/a
Price/Sales	2.99	Price/Sales Rank(?)	32
Market/Book	2.70	Market/Book Rank(?)	42
Beta	3.66	Beta Rank	2
Alpha	0.65	Alpha Rank	95

DOWNLOAD A FREE SAMPLE OF OUR FIVE PRIME THERAPEUTICS (FPRX) REPORT BY CLICKING HERE

ValuEngine Market Overview

ValuEngine Sector Overview